Back to News
Market Impact: 0.35
Edgewise Therapeutics Reports Third Quarter 2026 Financial Results and $1.348 billion Gain on Sevasemten Sale
Source: Nasdaq
Corporate EarningsCompany FundamentalsHealthcare & Biotech
Edgewise Therapeutics reported third-quarter 2026 net income of $1,166.2 million, or $10.71 per basic share and $9.65 per diluted share, compared with a $40.7 million net loss, or $0.39 per basic and diluted share, in Q3 2025. The article text is truncated and provides no explanation for the earnings swing.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
EWTX0.80
More News
- Raymond James raises Edgewise Therapeutics price target on FDA feedback
- Tech stocks are suffering their biggest selloff since Covid, as investors see premature end to AI datacenter boom
- Elon Musk's Tesla and SpaceX lose over $420 billion in combined market cap after midterms
- Qualcomm slides 9% after earnings, leading post-election chip stock sell-off
- Costco is taking aim at its May record high — how it got here and where's it going
- Neocloud IREN says $4 billion in annualized revenue being delayed due to customer request